A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to a preclinical study led by Weill Cornell Medicine investigators. The research reveals a promising strategy against this hard-to-treat malignancy, and more generally demonstrates a powerful new approach for the identification of effective regimens to treat genetically diverse cancers.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
